<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Cancer Drug Targets</journal-id><journal-id journal-id-type="iso-abbrev">Curr Cancer Drug Targets</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Current cancer drug targets</journal-title></journal-title-group><issn pub-type="ppub">1568-0096</issn><issn pub-type="epub">1873-5576</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC5623138</article-id><article-id pub-id-type="pmcid-ver">PMC5623138.1</article-id><article-id pub-id-type="pmcaid">5623138</article-id><article-id pub-id-type="pmcaiid">5623138</article-id><article-id pub-id-type="manuscript-id">NIHMS876482</article-id><article-id pub-id-type="pmid">28359247</article-id><article-id pub-id-type="doi">10.2174/1568009617666170330154054</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS876482</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA876482</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Method to Assess Interactivity of Drugs with Nonparallel Concentration-Effect Relationships</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="L">Liang</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Au</surname><given-names initials="JLS">Jessie L.-S.</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A2">b</xref><xref ref-type="aff" rid="A3">c</xref><xref ref-type="aff" rid="A4">d</xref><xref ref-type="aff" rid="A5">e</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wientjes</surname><given-names initials="MG">M. Guillaume</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A2">b</xref><xref ref-type="aff" rid="A3">c</xref><xref ref-type="author-notes" rid="FN1">*</xref></contrib></contrib-group><aff id="A1">
<label>a</label>The Ohio State University, Columbus, OH, USA</aff><aff id="A2">
<label>b</label>Optimum Therapeutics LLC, Carlsbad, CA, USA</aff><aff id="A3">
<label>c</label>Institute of Quantitative Systems Pharmacology, Carlsbad, CA, USA</aff><aff id="A4">
<label>d</label>University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA</aff><aff id="A5">
<label>e</label>Taipei Medical University, Taipei, Taiwan, ROC</aff><author-notes><corresp id="FN1"><label>*</label>Address correspondence to this author at the Optimum Therapeutics, LLC, 1815 Aston Ave STE 107, Carlsbad, CA 92008, USA; Tel: + 1-760-438-1155; <email>gwientjes@optimumtx.com</email></corresp><fn fn-type="COI-statement" id="FN2"><p id="P65"><bold>CONFLICT OF INTEREST</bold></p><p id="P66">The authors confirm that this article content has no conflict of interest.</p></fn></author-notes><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>17</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">299212</issue-id><fpage>735</fpage><lpage>755</lpage><pub-history><event event-type="nihms-submitted"><date><day>19</day><month>05</month><year>2017</year></date></event><event event-type="pmc-release"><date><day>13</day><month>10</month><year>2017</year></date></event><event event-type="pmc-live"><date><day>13</day><month>10</month><year>2017</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-17 19:25:32.847"><day>17</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms876482.pdf"/><abstract><sec id="S1"><title>Background</title><p id="P1">Commonly used methods for analyzing interactivity between drugs (<italic toggle="yes">e.g.</italic>, synergy, antagonism) such as isobologram, combination index, and curve shift are based on the Loewe Additivity principle of dose equivalence and the inherent assumption of similar concentration- effect (<italic toggle="yes">C-E</italic>) including parallel curves and equal maximum effects (<italic toggle="yes">E<sub>max</sub></italic>), and therefore are not suitable for drugs with dissimilar <italic toggle="yes">C-E</italic>. This study describes a new method that is without this limitation and has the additional advantage of enabling statistical analysis.</p></sec><sec id="S2"><title>Method and Results</title><p id="P2">The method comprises two steps. First, based on the dose equivalence principle, the experimentally obtained <italic toggle="yes">C-E</italic> of one drug was used to calculate the equally effective <italic toggle="yes">C-E</italic> of the other drug at no interactivity; the resulting two <italic toggle="yes">zero-interactivity C-E</italic> formed the upper and lower boundaries of Additivity Envelope. Next, 95% confidence intervals calculated from experimental data were added to Additivity Envelope to obtain Uncertainty Envelope (UE). Experimentally observed effects of drug combinations (<italic toggle="yes">C-E<sub>comb,observed</sub></italic>) located within UE indicate additivity whereas <italic toggle="yes">C-E<sub>comb,observed</sub></italic> located above or below UE indicate statistically significant (p&lt;0.05) synergy or antagonism, respectively. Additional <italic toggle="yes">in silico</italic> studies demonstrated the shape and size of Additivity Envelope, which determines the ability to detect drug interactivity, depending on the Drug A-to-B concentration ratios and the ratios of their <italic toggle="yes">C-E</italic> curve shape parameter. Analyses of experimental results of combinations of drugs with nonparallel <italic toggle="yes">C-E</italic> and/or unequal <italic toggle="yes">E<sub>max</sub></italic> indicated UE as more versatile and provided more information, compared to earlier methods.</p></sec><sec id="S3"><title>Conclusion</title><p id="P3">UE is a broadly applicable method for analysis, including statistical significance assessment, of drug interactivity.</p></sec></abstract><kwd-group><kwd>Combination therapy</kwd><kwd>drug-drug interactivity</kwd><kwd>Loewe-additivity</kwd><kwd>uncertainty envelope</kwd><kwd>statistically significant synergy</kwd><kwd>antagonism</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>